Bayer has extended its ongoing research collaboration with the Broad Institute of MIT and Harvard in the US by five years for the development of new cancer treatments.

Under the expanded deal, the firms intend to jointly identify three new additional investigational drugs (INDs) for new oncology targets.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In addition, the firms will generate related intellectual property and continue to openly share the obtained biological knowledge with the scientific community.

Bayer East Coast Innovation Centre vice-president and head Chandra Ramanathan said: “With Bayer’s commitment to oncology, we are excited to build on our relationship with the Broad Institute to translate discoveries into real benefit for patients.

“Having built a robust portfolio in the first few years, including the identification of multiple drug candidates, we are thrilled to continue our work with the Broad scientists to bring novel cancer treatments to the clinic.”

“With Bayer’s commitment to oncology, we are excited to build on our relationship with the Broad Institute to translate discoveries into real benefit for patients.”

Originally forged in 2013, the collaboration leverages Bayer’s experience on molecules and biologics drug discovery, along with the Broad Institute’s cancer research and chemical biology expertise.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It was further extended in 2015 to include genomics and drug discovery in cardiovascular disease.

The latest extension to 2023 will further see contribution of the institute’s expertise in biomarker development, patient selection and design of clinical trials.

Broad Institute chief scientific officer Todd Golub said: “The successful partnership between Broad and Bayer has already resulted in exciting advances in oncology drug discovery, with several programmes advancing toward the clinic.

“In order to successfully create new therapeutics that reach cancer patients, we must draw simultaneously on the skills of academia and industry.”